RASONQUE Approval Rewrites the Playbook for Revolution Medicines — A High-Conviction Long
Revolution Medicines just cleared a major regulatory hurdle with FDA approval of RASONQUE (daraxonrasib) for metastatic pancreatic adenocarcinoma. The approval unlocks what analysts peg as up to $11.5 billion in peak sales and converts the company from a pure clinical-stage name into a commercial oncology contender. Given the stock's recent pullbac…